We are live on ! Find out more

Celcuity

CELC

Market cap $4.08B

83.45 USD

-2.04

2.39%

At close Updated Sep 11, 4:00 PM EDT

Pre-market

After hours

85.00

+1.55

1.86%

1 day

-2.39%

5 days

-12.92%

1 month

-5.29%

3 months

-6.75%

6 months

-27.91%

Year to date

-17.01%

1 year

45.31%

5 years

289.04%

10 years

483.97%

About: Celcuity Inc is a clinical-stage biotechnology company developing targeted therapies for multiple solid tumors. Its candidate, gedatolisib, is a kinase inhibitor of the PI3K/AKT/mTOR (PAM) pathway, binding all class I PI3K isoforms and mTORC1/2, offering comprehensive inhibition with a mechanism and pharmacokinetics differentiated from other therapies. The Phase 3 VIKTORIA-1 trial, evaluating gedatolisib with fulvestrant, with or without palbociclib, in HR+/HER2- breast cancer, has completed enrollment and reported results for PIK3CA WT tumors, with cohort 2 (PIK3CA MT) also enrolled. Phase 3 VIKTORIA-2 and Phase 1b/2 CELC-G-201 trials, evaluating combinations in endocrine-resistant HR+/HER2- breast cancer and metastatic castration-resistant prostate cancer, are ongoing.

Employees: 155

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 21.2%

Neutral 72.7%

Negative 6.1%

Celcuity Inc. (CELC) Presents at Citigroup's Biopharma Back to School Summit 2026 Prepared Remarks Transcript

Celcuity Inc. (CELC) Presents at Citigroup's Biopharma Back to School Summit 2026 Prepared Remarks Transcript

Celcuity Inc. (CELC) Presents at Citigroup's Biopharma Back to School Summit 2026 Prepared Remarks Transcript

Celcuity To Participate in Upcoming Investor Conferences

MINNEAPOLIS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that Brian Sullivan, Chief Executive Officer and Co-founder of Celcuity, will present and be available for one-on-one investor meetings at the following investor conferences:

Celcuity To Participate in Upcoming Investor Conferences

Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer

MINNEAPOLIS, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for multiple solid tumor indications, today announced the submission of its supplemental New Drug Application (“sNDA”) to the U.S. Food and Drug Administration (“FDA”) for REVTORPYK™ (gedatolisib) for the treatment of patients with hormone receptor positive (“HR+”), human epidermal growth factor receptor 2 negative (“HER2-”), locally advanced or metastatic breast cancer (“ABC”) with a PIK3CA mutation, following progression on or after treatment with at least one line of endocrine therapy.

Celcuity Submits sNDA to FDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer

Celcuity: REVTORPYK Is Now A Commercial Story

Celcuity Inc. remains a Buy as the REVTORPYK/gedatolisib FDA approval and rapid NCCN Category 1 inclusion de-risk clinical and commercial adoption. CELC's financials reflect a front-loaded commercial investment, with SG&A surging for launch, but a strengthened $754M cash position provides funding visibility into 2029. VIKTORIA-1 data show REVTORPYK delivers a step-change in efficacy and tolerability, supporting rapid physician adoption and a potential blockbuster franchise.

Celcuity: REVTORPYK Is Now A Commercial Story

Celcuity Analysts Slash Their Forecasts After Q2 Loss

Celcuity Inc (NASDAQ:CELC) reported a narrower-than-expected loss for the second quarter on Thursday.

Celcuity Analysts Slash Their Forecasts After Q2 Loss

Celcuity Inc. (CELC) Q2 2026 Earnings Call Transcript

Celcuity Inc. (CELC) Q2 2026 Earnings Call Transcript

Celcuity Inc. (CELC) Q2 2026 Earnings Call Transcript

Celcuity Q2 Earnings Call Highlights

Celcuity NASDAQ: CELC said it remains on track to begin commercial shipments of REVTORPYK, its gedatolisib therapy for certain patients with advanced breast cancer, late in the third quarter of 2026 following its recent FDA approval.

Celcuity Q2 Earnings Call Highlights

Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update

MINNEAPOLIS, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced financial results for the second quarter ended June 30, 2026 and other recent business developments.

Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC

NEW YORK, Aug. 6, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Celcuity Inc. ("Celcuity" or the "Company") (NASDAQ: CELC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Celcuity Inc. - CELC

Celcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference Call

MINNEAPOLIS, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Celcuity Inc. (Nasdaq: CELC), a commercial-stage biotechnology company focused on developing and commercializing targeted therapies for the treatment of multiple solid tumor indications, today announced that it will release its financial results for the second quarter 2026 after the market closes on Thursday, August 13, 2026. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Daylight Time to discuss the results and provide a corporate update.

Celcuity Schedules Release of Second Quarter 2026 Financial Results and Webcast/Conference Call

See News Rankings

Price charts implemented using Lightweight Charts™